Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors – Results from the PAN Study

1. OBJECTIVE: Chronic hepatitis C virus infections (HCV) cause a significant public health burden. Introduction of telaprevir (TVR) and boceprevir (BOC) has increased sustained virologic response rates (SVR) in genotype 1 patients but were accompanied by higher treatment costs and more side effects....

Descripción completa

Detalles Bibliográficos
Autores principales: Stahmeyer, Jona T., Rossol, Siegbert, Bert, Florian, Böker, Klaus H. W., Bruch, Harald-Robert, Eisenbach, Christoph, Link, Ralph, John, Christine, Mauss, Stefan, Heyne, Renate, Schott, Eckart, Pfeiffer-Vornkahl, Heike, Hüppe, Dietrich, Krauth, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964984/
https://www.ncbi.nlm.nih.gov/pubmed/27467772
http://dx.doi.org/10.1371/journal.pone.0159976

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964984/
https://www.ncbi.nlm.nih.gov/pubmed/27467772
http://dx.doi.org/10.1371/journal.pone.0159976

Ejemplares similares